Ann: Antisense Therapeutics transitions to new Board Chair, page-46

Stock of the week

Power’s stock of the week is Antisense Therapeutics (ASX:ANP)

The company has received positive feedback from the Type-C meeting with the US FDA (trial design, dosage, endpoints were all acceptable) on its Phase-2 ATL1102 trial, with the decision on fast designation request expected in August. ATL1102 is an antisense inhibitor to treat Duchenne muscular dystrophy (DMD), a fatal genetic muscle inflamation disorder that affects every 3,500 to 5,000 males worldwide. “The other area of interest with Antisense is that its long-serving chairman Bob Moses is stepping down to make way for Dr Charmaine Gittleson, very highly credentialed executive from CSL,” Power said.